Administration (FDA) and Health Canada, the manufacturer of aprotinin temporarily suspended worldwide marketing of the drug due to safety concerns on November 5, 2007 . On the same day, we decided to replace aprotinin with EACA as our agent of choice for the prevention of fibrinolysis-induced bleeding.
In a recent review of the data on antifibrinolytic therapy in paediatric cardiac surgery, we noted that there are large variations in patients, surgical procedures, and dosing regimens within published trials. 1 Although an inverse correlation between age and both postoperative blood loss and transfusion requirement has been established in paediatric cardiac surgery, 8 no trials of antifibrinolytic agents have specifically focused on infants aged up to 1 yr. Since the haemostatic response to CPB in these patients is quite different from that of older children (lower platelet count and fibrinogen, higher blood loss and transfusion requirement), 8 9 we decided to investigate this particular population. Neonates were excluded and analysed in a separate study 10 because they have a higher surgical risk, blood loss, and transfusion rates. 8 The aim of this analysis was the comparison of two large cohorts of consecutive infants treated with either aprotinin during an initial 16-month period or EACA during a subsequent 26-month period. There was no gap between the two cohorts and the primary outcomes were blood loss and transfusion requirements. This comparison remains highly topical as Health Canada after a comprehensive safety review authorized aprotinin for patients undergoing coronary artery bypass grafting (http://www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/_2011/2011_124-eng.php), and the European Medicines Agency also recommended lifting the suspension of aprotinin (http://www.ema.europa.eu/docs/en_GB/document_ library/Press_release/2012/02/WC500122914.pdf).
Methods

Study design
The study was approved by the local ethics committee; the requirement for written informed consent was waived by the board. We retrospectively analysed the perioperative data of all infants (age 31-365 days) undergoing cardiac surgery with CPB between July 1, 2006, and December 31, 2009 (n¼252). Only patients undergoing primary cardiac surgery were included. We excluded 22 patients because no data regarding antifibrinolytic therapy could be retrieved from the chart (10 aprotinin patients and 12 EACA patients). Until November 5, 2007 , all patients were treated with aprotinin in accordance with the institutional protocol in use at the time (n¼90, referred to as the aprotinin group). On November 6, 2007, we changed our protocol by replacing aprotinin with EACA. In total, 140 patients were treated with EACA (the EACA group). All data were prospectively collected as part of a national quality assurance programme. Three patients were excluded because they could not be weaned from CPB and required transitioning to extracorporeal membrane oxygenation (aprotinin n¼2, EACA n¼1). After these exclusions, the study cohort contained data from 227 patients (aprotinin¼88, EACA¼139) (Fig. 1) .
Institutional protocol
The institutional protocol for aprotinin (Trasylol, Bayer Pharmaceuticals, Leverkusen, Germany) consisted of a bolus of The protocols and the team of surgeons, anaesthetists, and paediatric cardiologists remained in all other aspects unchanged during the course of the study. We have previously described our anaesthetic management of these patients in detail. 12 CPB was performed using a membrane oxygenator FFP was transfused at an international normalized ratio of .1.8 and platelets were transfused at a platelet count ,50 000 ml 21 . The indication for re-exploration in cases of postoperative bleeding was determined by the attending surgeon.
Measurements
We analysed patient characteristic and perioperative clinical data. All patients were assigned a Risk Adjustment for Congenital Heart Surgery (RACHS-1) score and an Aristotle basic score, 13 and these were used to assess comparability between the cohorts. The primary outcome parameter was postoperative blood loss by weight as measured by chest tube output (CTO) during the first 24 h after surgery. Secondary outcome parameters were the volume of transfused allogeneic blood products (including allogeneic products added to the CPB priming solution) during the first 24 h after surgery, subsequently postoperative transfusion requirements with exclusion of the intraoperative transfusions, and the incidence of reoperation for bleeding. Additionally, several clinical outcome criteria were monitored for safety issues. Postoperative renal dysfunction was graded according to the paediatric modified RIFLE criteria (Risk -InjuryFailure -Loss -End). 14 Urine output alone is not a good determinant of acute renal failure on the first postoperative day. The estimated creatinine clearance was calculated using the Schwartz formula 15 at 24 h after operation because postoperative creatinine levels peak at this time. 16 Echocardiography was performed on every patient on the first postoperative day and before discharge from the paediatric intensive care unit. The presence or absence of vascular thrombosis in the heart and the large vessels as diagnosed using ultrasound was documented. Neurological events (specifically seizures, stroke, and intracranial bleeding, diagnosed clinically and confirmed by CT scan or ultrasound) were also documented. Finally, all-cause in-hospital mortality was recorded.
Statistical analysis
Descriptive statistics are provided as means and standard deviations for normally distributed data. Medians and interquartile ranges are provided for non-normally distributed data. Categorical data are described using absolute and relative frequencies and displayed in contingency tables. Relative risks are presented with 95% confidence intervals (CI). Statistical tests for group comparisons of continuous parameters are given by the t-tests or Mann-Whitney U-tests depending on the distribution of the data. Categorical variables were compared between the groups by x 2 tests, and Fisher's exact test depending on the expected cell counts of the corresponding cross-tabs. For the primary outcome, an additional sensitivity analysis was performed in order to further substantiate our findings. Therefore, CTO was log-transformed to obtain a normal distribution which renders the application of parametric analyses possible. Accordingly, group comparisons were repeated in a univariate and multivariate setting by the t-test and linear regression analysis.
All tests were two-sided and conducted in an explorative manner at a 5% level of significance. The statistical analyses were performed by SPSS for Windows 19.0 statistical software package (SPSS Inc., Chicago, IL, USA) and R for statistical computing (The R Foundation for Statistical Computing, Vienna, Austria).
Results
The two groups were comparable with respect to all recorded patient characteristics and preoperative data (Table 1 ). There were no significant differences between the groups regarding intraoperative risk parameters and complexity of the operations as graded by RACHS-1 and Aristotle basic scores (Table 1) .
CTO at 24 h after operation was significantly lower in the aprotinin group: 18 ml kg 21 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) Table 1 . The similarity of results stresses the robustness of the finding. Likewise, it also gives further evidence that groups can be validly compared as the minor; non-significant differences investigated in Table 1 only show a negligible influence on the assessment. There were no statistically significant differences with respect to reoperation for bleeding, transfusion requirements, and donor exposures, either at 24 h values or at subsequent times ( (Table 3) . With regard to clinical outcome parameters, there were no statistically significant differences in renal dysfunction, vascular thrombosis, neurological events, or in-hospital mortality (Table 4) .
Discussion
The major finding of this single-centre retrospective analysis was that a protocol change from aprotinin to EACA in infants (aged 31-365 days) undergoing cardiac surgery led to increased postoperative CTO. While this difference was statistically significant, we found no evidence of a clinically significant difference. This increase was not associated with an increase in allogeneic transfusions or rate of reoperation for bleeding.
Further analyses did not suggest associated adverse changes for a range of major perioperative outcome parameters.
Efficacy
We compared two sequential treatment cohorts. These two cohorts were well matched with respect to numerous preand intraoperative characteristics. Nonetheless, we additionally performed a sensitivity analysis which strengthened our finding that the increased CTO in the EACA group was attributable to the lower efficacy of EACA and not confounding issues.
In a recent systematic review of prospective trials of blood conserving measures in paediatric patients, a meta-analysis could not be performed because of the wide variation in the outcome measures used. Nevertheless, based on qualitative review, the author determined that there was sufficient evidence to conclude that the use of an antifibrinolytic decreased postoperative bleeding. 1 The assessment of the relative efficacies of aprotinin and EACA in paediatric cardiac surgery was exclusively based on a prospective trial which found that both medications similarly reduced blood loss. In contrast to our study, the patients in that prospective trial were aged between 2.7 months and 13 yr and the dosage of aprotinin was much lower. 17 Observational data are also rare in this field. Recently, an analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database suggested no difference between aprotinin and EACA in a mixed paediatric cohort. 18 Of note, the primary outcome measure in that study was the incidence of reoperation for bleeding and neither blood loss nor transfusions were assessed. Our measured CTO at 24 h in the aprotinin cohort is similar to losses reported in another study evaluating blood loss in infants (although data regarding the use of antifibrinolytic medications were not provided). 9 There is evidence that both aprotinin and EACA have antiinflammatory properties, but it remains controversial as to whether one is superior to the other in this respect. 19 -21 Hence, it is only possible to speculate as to whether the difference in CTO between our two groups can be attributed to differing anti-inflammatory effects of aprotinin and EACA. It is noteworthy that fibrinogen, which is a coagulation factor and an acute-phase protein, was also higher in EACA patients on postoperative day 1. Differential biochemical markers of inflammation like interleukins were not routinely measured during the period of investigation and the study was not designed to include closer analysis of the drainage fluid. The efficacy of any haemostatic therapy cannot be assessed solely by measurements of CTO. We also performed an analysis of transfusion requirements and rates of reoperation for bleeding. Our results showed that although statistically significant, the absolute difference of the mean CTO of 5 ml kg 21 is low in relation to the mean volume of transfusion of about 175 ml 21 kg 21 (RBC, FFP, and platelets) ( Table 2) . We were unable to demonstrate a clinically significant impact of our protocol change on transfusion requirements or reoperation for bleeding. The benefit of aprotinin with respect to CTO might be insignificant in comparison with the large transfusion requirement (on average, double the circulating volume of the patient) over the first 24 h. Replacing aprotinin by EACA, which according to published trials potentially is less effective in its blood-sparing effect, entails the risk that physicians might have pre-emptively transfused haemostatic blood products in EACA patients. Therefore, we additionally compared haematological data throughout the perioperative course. With regard to postoperative laboratory measurement, it should be noted that all patients were transfused with FFP, which contains adult concentrations of coagulation factors. The large amount of transfused plasma ( 100 ml 21 kg 21 ) surely affects the coagulation system, but as the amount did not differ between the two groups, a similar influence on measurements should be expected. In this study, we analysed data from infants only and excluded neonates. Neonates require special consideration for several reasons: immaturity of their hepatic function resulting in a relative coagulation factor deficiency, 2 3 higher surgical risk, higher blood loss, and higher transfusion rates. 8 A post hoc comparison of this sample group with our 
Clinical outcome
In order to determine the relative safety of aprotinin and EACA, we analysed several major clinical outcome criteria but we could not detect any significant differences. We performed a literature search to identify any relevant previous work in order to put our results into context. This proved to be difficult as there are only a few existing studies. The majority of similar work has either focused on neonates or on mixed cohorts with wide variations in age. The incidence of the various stages of renal damage according to the RIFLE criteria did not significantly differ between the two groups. A review by Eaton 1 identified eight studies in children investigating renal outcome after aprotinin treatment. Only one of these, a retrospective analysis in children aged between 15 days and 6 yr, suggested an increased renal risk (they reported moderate impairment of tubular function). 22 All others could not prove an increased risk of renal damage after aprotinin treatment. Nonetheless, due to the small patient numbers involved, the authors could not definitively rule out increased renal risk associated with aprotinin. To date, we have not been able to identify any studies comparing EACA with control regarding the impact on renal function in paediatric cardiac surgery. Besides our own analysis of neonates, 10 only one other retrospective analysis has compared EACA with aprotinin in children (neonates up to teenagers). 23 This study found that the aprotinin-treated patients had a higher incidence of kidney injury at discharge. It is important to note that in paediatric cardiac surgery, age is an independent predictor of postoperative renal dysfunction. 24 The kidney in the infant is still developing 25 and conclusions drawn from studies of mixed paediatric populations again cannot necessarily be extended to infants. As mentioned in several publications, all antifibrinolytic therapies carry the risk of vascular thrombosis. This risk is pronounced in paediatric patients because of their small vessels, prolonged immobility, artificial shunts, low flow states, central venous catheter requirements, and high blood viscosities. 26 All patients underwent routine ultrasound of the heart and the great vessels at least twice during their postoperative course. Using this regular monitoring, we detected severe postoperative thrombotic vascular events in 6-7% of cases without a significant difference between the two groups. This rate is a little less than that observed in neonates, 10 and might be attributable to the larger vessel diameters in infants. One retrospective analysis in neonates reported a thrombosis rate of 4.6%, but it was not specified whether cardiac catheterization or ultrasound examination was routinely performed after surgery. 16 Neurological complications occurred rarely during the period of investigation and there was no significant difference between the groups. Seizures, a recently described adverse effect of the lysine analogue tranexamic acid in adults, 27 were observed in only three patients in each group (3% in the aprotinin group and 2% in the EACA group). This is within the reported range in a previous analysis of paediatric patients up to 20 kg treated with either aprotinin or tranexamic acid. 28 We were unable to identify any data regarding a specifically pro-convulsive effect of EACA in cardiac surgery in adults or children.
Limitations
The retrospective nature of this analysis is a weakness. We analysed the perioperative data of a large cohort of consecutive infants treated according to a strict institutional protocol. Aprotinin was replaced by EACA at a specific date and so there was no time delay between the two cohorts. Apart from the antifibrinolytic treatment all other aspects, including the team of surgeons, anaesthetists, and paediatric cardiologists and each department's protocols remained unchanged. The risk of a time-dependent bias was minimized by the additional performance of a sensitivity analysis. Although our study population was very large relative to other similar studies, we cannot exclude that the study was underpowered to detect all differences between the two groups. We restricted our cohort to infants aged between 31 and 365 days who had not undergone a previous cardiac surgical procedure in order to maximize the homogeneity of the groups with respect to patient and procedure factors. Accordingly, caution is required before generalizing our findings to broader paediatric cardiac surgical populations.
Conclusion
In this analysis of 227 consecutive infants undergoing primary cardiac surgery, replacement of aprotinin by EACA was associated with increased volume of postoperative CTO, although transfusion requirements and major clinical outcome criteria did not differ. The increased CTO in the EACA group can probably be attributed to the change in antifibrinolytic medication. Randomized controlled trials are needed to establish the safety of each antifibrinolytic medication used in paediatric cardiac surgery. In order to avoid bias, such a trial should be performed double-blinded and placebo-controlled. This need is particularly urgent in view of the fact that none of the commonly used antifibrinolytic drugs has FDA approval for their use in paediatric cardiac surgery.
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